Latest Content

More than three years after cancer centers first sounded the alarm on chemotherapy shortages, the problem still hasn't gone away.

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and neuroendocrine cancers.

Learn how to support a friend with cancer by showing up, listening, staying connected and treating them like the same person they were before diagnosis.

After 10 years of living with stage 4 ovarian cancer, one survivor shares why she continues to raise awareness each September and urges women to know the signs, make time for gynecologic care and advocate for themselves.

Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.

Medicare will narrow ostomy suppliers to about eight national contracts, and advocate Ellyn Mantell says a poor fit can put patients in the hospital.

Prostate cancer treatment has advanced rapidly in five years. Explore key FDA approvals, improved treatments and what these changes mean for patients.

FDA grants accelerated approval to Hyrnuo (sevabertinib) for certain patients with HER2-mutated, advanced or metastatic non-small cell lung cancer.

The FDA has withdrawn its accelerated approval of Krazati combined with Erbitux for adults with KRAS G12C-mutated colorectal cancer that is locally advanced or has spread to other parts of the body.

Dr. Andrew Ip answers common lymphoma questions, from diagnosis and treatment options to CAR T-cell therapy, side effects and hope for patients.

Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.

Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.

A new study found alcohol-attributable cancer deaths in the U.S. rose from 11,361 in 1990 to 23,126 in 2023, with men and older adults most affected.